SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
announced its financial results for the quarter ended March 31,
2017. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
(including Exhibit 99.1 related thereto) shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly
provided by specific reference in such a filing.
hereto as Exhibit 99.1, the Company is holding a public
conference call and webcast on May 11, 2017, at 5:00 p.m. ET,
during which the Company will provide the investor presentation
attached as Exhibit 99.2 to this Current Report.
99.2 related thereto) shall not be deemed filed for purposes of
Section 18 of the Exchange Act, or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference into any filing under the Securities Act, or the
Exchange Act, except as expressly provided by specific reference
in such a filing.
furnished, and not filed:
|
Exhibit
No.
|
Description
|
||
|
99.1
|
Press Release issued on May 11, 2017
|
||
|
99.2
|
Investor Presentation dated May 11, 2017
|
||
About SELECTA BIOSCIENCES, INC. (NASDAQ:SELB)
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The Company’s product candidates are in development. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s technology allows for the design of SVP therapies that can stimulate immune responses against a range of relevant antigens. Its initial immune-stimulating product candidate is a synthetic vaccine against nicotine for the market of smoking cessation and relapse prevention. SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Recent Trading Information
SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) closed its last trading session down -0.29 at 13.51 with 27,663 shares trading hands.
